# Orbus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/orbus-therapeutics

- Industry: Biotechnology
- Headquarters: Palo Alto, US
- Website: www.orbustherapeutics.com
- Total disclosed funding: $41M
- Latest round: Series A (Jul 27, 2020)
- Investors on record: 5

## About

Orbus Therapeutics, Inc. focuses on developing and commercializing therapeutic products for rare diseases, particularly concentrating on innovative treatments that enhance patient health outcomes.Founded in 2012, Orbus Therapeutics, Inc. operates out of Palo Alto, US, specializing in therapies for rare diseases. The company has secured a total of 4 funding deals, with its most recent financing round being a Series A completed in July 2020, raising USD 10.00 mn from investors including Abingworth, Adams Street Partners, H.I.G. BioHealth Partners, and Longitude Capital. The company's founders, Jason Levin and Victor Levin, have a history of expertise in the biotech sector, contributing to Orbus's strategic direction. As of now, Orbus has not undergone any significant pivots in its business approach.Orbus Therapeutics specializes in the development and commercialization of innovative therapeutic products aimed at addressing the needs of patients suffering from rare diseases. The company's core focus is centered on eflornithine, a treatment targeted towards specific life-threatening conditions, including grade 3 astrocytoma. The drug works by inhibiting an enzyme necessary for cell growth, thereby slowing down or halting the progression of certain tumors. Currently, Orbus is primarily engaged in the North American and European markets, where it seeks to improve patient outcomes through its specialized treatment offerings. The end users of Orbus’s products include patients diagnosed with rare diseases, their families, and healthcare providers responsible for their care.Orbus Therapeutics generates revenue through the commercialization of its therapeutic product, eflornithine, which is positioned within a specialized pharmaceutical segment. The company engages in direct-to-consumer sales as well as partnerships with healthcare providers and institutions that facilitate access to its treatments. Transactions are structured around the sale of eflornithine, with healthcare entities procuring the medication to administer to eligible patients. The pricing model is designed to reflect the unique value of treating rare conditions, ensuring that access to effective therapies is prioritized. As Orbus continues to expand its market presence, it reinforces its commitment to providing solutions for underserved patient populations, thereby solidifying its role within the rare disease therapeutic landscape.In July 2020, Orbus Therapeutics, Inc. raised USD 10.00 mn through Series A financing from returning investors and a new participant, Abingworth. This funding will be utilized to support the development of new therapeutic products and expand market access. The company aims to explore opportunities in additional European markets and further penetrate the North American landscape by 2023, thereby broadening its outreach to patients in need of innovative treatments. Specific new products are in the pipeline, although exact release dates have not been outlined.

## Funding rounds

- Series A, Jul 27, 2020, $10M — Abingworth, Adams Street Partners, H.I.G. BioHealth Partners, Longitude Capital
- Series A, Aug 8, 2017, $13M — Agent Capital
- Series A, Aug 7, 2015, $18M — Adams Street Partners, H.I.G. BioHealth Partners, Longitude Capital

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series A
- H.I.G. BioHealth Partners (https://capitalatlas.ai/funds/h-i-g-biohealth-partners) — Series A
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A
- Agent Capital (https://capitalatlas.ai/funds/agent-capital) — Series A
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series A